Heres a comparison to semaglutide showing that the novel compound leads to more weight loss (blue dots are semaglutide, red dots are the new compound, black dots are placebo, and the Y-axis is body weight): Hitting different receptors may also mean an impact on tolerability - one of the big issues with these medications in the real world
However, Phase 1 and Phase 2 clinical trial data indicated elevated transaminase enzyme levels, indicating the potential for liver dysfunction
Comments here go into the FDA's general administrative record on the substance
Ahlqvist E, Storm P, Krjmki A, Martinell M, Dorkhan M, Carlsson A, et al
KLOW fits when inflammation is in the picture rosacea, post-procedure redness, reactive or flushing-prone skin
Los resultados iniciales del estudio muestran que las personas pierden un mayor porcentaje de peso, hasta un 30% de su peso corporal, cuando toman retatrutida en comparacin con el placebo